000275963 001__ 275963
000275963 005__ 20240926155221.0
000275963 0247_ $$2pmid$$apmid:37160571
000275963 0247_ $$2ISSN$$a1932-2259
000275963 0247_ $$2ISSN$$a1932-2267
000275963 0247_ $$2doi$$aDOI: 10.1007/s11764-023-01392-3 
000275963 0247_ $$2doi$$aDOI: 10.1007/s11764-023-01392-3
000275963 037__ $$aDKFZ-2023-00945
000275963 041__ $$aEnglish
000275963 082__ $$a610
000275963 1001_ $$aHiensch, Anouk E$$b0
000275963 245__ $$aModerators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis.
000275963 260__ $$aNew York, NY [u.a.]$$bSpringer$$c2024
000275963 3367_ $$2DRIVER$$aarticle
000275963 3367_ $$2DataCite$$aOutput Types/Journal article
000275963 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1727358694_12791
000275963 3367_ $$2BibTeX$$aARTICLE
000275963 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275963 3367_ $$00$$2EndNote$$aJournal Article
000275963 500__ $$a2024 Oct;18(5):1492-1503
000275963 520__ $$aThis individual participant data meta-analysis (IPD-MA) assesses exercise effects on self-reported cognitive functioning (CF) and investigates whether effects differ by patient-, intervention-, and exercise-related characteristics.IPD from 16 exercise RCTs, including 1987 patients across multiple types of non-metastatic cancer, was pooled. A one-stage IPD-MA using linear mixed-effect models was performed to assess exercise effects on self-reported CF (z-score) and to identify whether the effect was moderated by sociodemographic, clinical, intervention- and exercise-related characteristics, or fatigue, depression, anxiety, and self-reported CF levels at start of the intervention (i.e., baseline). Models were adjusted for baseline CF and included a random intercept at study level to account for clustering of patients within studies. A sensitivity analysis was performed in patients who reported cognitive problems at baseline.Minimal significant beneficial exercise effects on self-reported CF (β=-0.09 [-0.16; -0.02]) were observed, with slightly larger effects when the intervention was delivered post-treatment (n=745, β=-0.13 [-0.24; -0.02]), and no significant effect during cancer treatment (n=1,162, β=-0.08 [-0.18; 0.02]). Larger effects were observed in interventions of 12 weeks or shorter (β=-0.14 [-0.25; -0.04]) or 24 weeks or longer (β=-0.18 [-0.32; -0.02]), whereas no effects were observed in interventions of 12-24 weeks (β=0.01 [-0.13; 0.15]). Exercise interventions were most beneficial when provided to patients without anxiety symptoms (β=-0.10 [-0.19; -0.02]) or after completion of treatment in patients with cognitive problems (β=-0.19 [-0.31; -0.06]). No other significant moderators were identified.This cross-cancer IPD meta-analysis observed small beneficial exercise effects on self-reported CF when the intervention was delivered post-treatment, especially in patients who reported cognitive problems at baseline.This study provides some evidence to support the prescription of exercise to improve cognitive functioning. Sufficiently powered trials are warranted to make more definitive recommendations and include these in the exercise guidelines for cancer survivors.
000275963 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000275963 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000275963 650_7 $$2Other$$aCancer
000275963 650_7 $$2Other$$aCognitive functioning
000275963 650_7 $$2Other$$aExercise
000275963 650_7 $$2Other$$aIndividual participant data meta-analysis
000275963 650_7 $$2Other$$aSurvivorship
000275963 7001_ $$aBeckhaus, Julia$$b1
000275963 7001_ $$aWitlox, Lenja$$b2
000275963 7001_ $$aMonninkhof, Evelyn M$$b3
000275963 7001_ $$aSchagen, Sanne B$$b4
000275963 7001_ $$avan Vulpen, Jonna K$$b5
000275963 7001_ $$aSweegers, Maike G$$b6
000275963 7001_ $$aNewton, Robert U$$b7
000275963 7001_ $$aAaronson, Neil K$$b8
000275963 7001_ $$aGalvão, Daniel A$$b9
000275963 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b10$$udkfz
000275963 7001_ $$aStuiver, Martijn M$$b11
000275963 7001_ $$aMesters, Ilse$$b12
000275963 7001_ $$aKnoop, Hans$$b13
000275963 7001_ $$aGoedendorp, Martine M$$b14
000275963 7001_ $$aBohus, Martin$$b15
000275963 7001_ $$aThorsen, Lene$$b16
000275963 7001_ $$aSchulz, Karl-Heinz$$b17
000275963 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina E$$b18$$udkfz
000275963 7001_ $$aUlrich, Cornelia M$$b19
000275963 7001_ $$aSonke, Gabe S$$b20
000275963 7001_ $$avan Harten, Wim H$$b21
000275963 7001_ $$aWinters-Stone, Kerri M$$b22
000275963 7001_ $$aVelthuis, Miranda J$$b23
000275963 7001_ $$aTaaffe, Dennis R$$b24
000275963 7001_ $$avan Mechelen, Willem$$b25
000275963 7001_ $$aKersten, Marie José$$b26
000275963 7001_ $$aNollet, Frans$$b27
000275963 7001_ $$aWiskemann, Joachim$$b28
000275963 7001_ $$aBuffart, Laurien M$$b29
000275963 7001_ $$aMay, Anne M$$b30
000275963 773__ $$0PERI:(DE-600)2388888-X$$aDOI: 10.1007/s11764-023-01392-3$$n5$$p1492-1503$$tJournal of cancer survivorship$$v18$$x1932-2259$$y2024
000275963 909CO $$ooai:inrepo02.dkfz.de:275963$$pVDB
000275963 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000275963 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000275963 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000275963 9141_ $$y2023
000275963 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000275963 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000275963 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000275963 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000275963 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER SURVIV : 2022$$d2023-08-25
000275963 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000275963 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000275963 980__ $$ajournal
000275963 980__ $$aVDB
000275963 980__ $$aI:(DE-He78)C110-20160331
000275963 980__ $$aUNRESTRICTED